Jim Cramer's Stop Trading: GW Pharmaceuticals Is for Real

NEW YORK (TheStreet) -- "I think this is becoming a non-speculative stock," TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said of GW Pharmaceuticals (GWPH) on CNBC's "Cramer's Stop Trading" segment. 

The company has released its preliminary data for Epidiolex, its cannabinoid treatment aimed at treatment-resistant epilepsy in children. 

Cramer argued that the U.S. doesn't seem to understand the importance of medical marijuana, as it would be illegal for companies to create the non-laced marijuana treatment that GW Pharmaceuticals, a British-based company, has. 

After 12 weeks, the drug showed at least a 50% reduction in seizures for 48% of the patients, with 15% of patients reportedly being seizure-free. 

Cramer said he believes the Food and Drug Administration will approve this treatment, as it is proving helpful to these children. 

He concluded that GW Pharmaceuticals is a "real company, doing real things."


-- Written by Bret Kenwell in Petoskey, Mich.

5 Reasons So Many Seniors Fall Victim to I.D. Theft

Pro Golfers Like Mickelson Hit Hole in One on Investing Tips

It's Time for Your Midyear Financial Checkup

Why Would Anyone Want to Buy Yelp?

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Tuesday Turnaround: Micron, Autonomous Driving, and J.C. Penney

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Cable Stock Investors Should Keep an Eye On Wireless Broadband's Rise

Trump Blinks on China Trade War That's Looking Harder to Win

Trump Blinks on China Trade War That's Looking Harder to Win

Monday Madness: GE, China, and Micron

Monday Madness: GE, China, and Micron

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly